In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 201 to 222 of 222

Sort by

Keyword or reference number: Treating this as aRemove Keyword or reference number: Treating this as a filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]	Technology appraisal guidance	12 June 2026
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]	Highly specialised technology	TBC
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351	Technology appraisal guidance	TBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]	Technology appraisal guidance	TBC
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over ID6557	Technology appraisal guidance	TBC
Transvenous embolisation for treating cerebrospinal fluid-venous fistula associated with spontaneous intracranial hypotension	Interventional procedures guidance	25 March 2026
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]	Technology appraisal guidance	7 May 2026
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]	Technology appraisal guidance	TBC
Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]	Technology appraisal guidance	TBC
Upadacitinib for treating giant cell arteritis [ID6299]	Technology appraisal guidance	TBC
Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468]	Technology appraisal guidance	TBC
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]	Technology appraisal guidance	TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]	Technology appraisal guidance	TBC
VER-01 for treating chronic low back pain [ID6638]	Technology appraisal guidance	TBC
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099	Technology appraisal guidance	TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]	Technology appraisal guidance	TBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]	Technology appraisal guidance	29 April 2026
Vosoritide for treating achondroplasia in people 4 months and over [ID6488]	Technology appraisal guidance	TBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]	Highly specialised technology	TBC
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]	Technology appraisal guidance	TBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]	Technology appraisal guidance	TBC
Zuranolone for treating postnatal depression [ID6431]	Technology appraisal guidance	TBC

Results per page

10
25
50
All